Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.

No abstract

No abstract

Eculizumab provided benefit for women with PNH during pregnancy, as evidenced by a high rate of fetal survival and a low rate of maternal complications. (ClinicalTrials.gov number, NCT01374360.).

identifi ed the common presenting symptoms of PAH as dyspnea on exertion, edema, fatigue, and chest pain; in this registry, the median time between P ulmonary arterial hypertension 1 (PAH) is an uncommon disorder characterized by abnormal increases in pulmonary artery pressure (PAP), normal pulmonary capillary wedge pressure (PCWP), and increased pulmonary vascular resistance (PVR). 2 PAH results in right ventricular pressure/volume overload leading to right ventricular failure and death. 3 Patients with PAH are often diagnosed late in the course of the disease when the pathologic changes are advanced and irreversible. [4][5][6][7] Diagnosis of PAH at this stage is associated with poor prognosis for survival, 8,9 underscoring the importance of early disease recognition and treatment. Abbreviations: 6MWD 5 6-min walk distance; LVEDP 5 left ventricular end-diastolic pressure; PAH 5 pulmonary arterial hypertension; PAP 5 pulmonary artery pressure; PCWP 5 pulmonary capillary wedge pressure; PVR 5 pulmonary vascular resistance; RAP 5 right atrial pressure; REVEAL 5 Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management; RHC 5 right-sided heart catheterization

No abstract

No abstract

No abstract